Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo

M. Huppert, D. Pappagianis, S. H. Sun, I. Gleason-Jordan, M. S. Collins, K. R. Vukovich

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Amphotericin B, the principal drug used for treating systemic mycoses possesses undesirable toxic properties. The ability of this antibiotic to potentiate antifungal activity of other compounds suggests that lower doses of amphotericin B could be used in combination with a second drug without loss of therapeutic efficacy. In vitro tests demonstrated that amphotericin B potentiated rifampin against the mycelial growth phase of Coccidioides immitis but not against the spherule endospore phase. Therapy for murine coccidioidomycosis with a combined amphotericin B rifampin regimen was not better than treatment with amphotericin B alone; in fact, combined drugs may have been even less effective. This would have clinical significance for therapy of concurrent infections.

Original languageEnglish (US)
Pages (from-to)406-413
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume9
Issue number3
StatePublished - 1976

Fingerprint

Coccidioides
Amphotericin B
Rifampin
Pharmaceutical Preparations
Coccidioidomycosis
Mycoses
Poisons
Therapeutics
In Vitro Techniques
Anti-Bacterial Agents
Growth
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Huppert, M., Pappagianis, D., Sun, S. H., Gleason-Jordan, I., Collins, M. S., & Vukovich, K. R. (1976). Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo. Antimicrobial Agents and Chemotherapy, 9(3), 406-413.

Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo. / Huppert, M.; Pappagianis, D.; Sun, S. H.; Gleason-Jordan, I.; Collins, M. S.; Vukovich, K. R.

In: Antimicrobial Agents and Chemotherapy, Vol. 9, No. 3, 1976, p. 406-413.

Research output: Contribution to journalArticle

Huppert, M, Pappagianis, D, Sun, SH, Gleason-Jordan, I, Collins, MS & Vukovich, KR 1976, 'Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo', Antimicrobial Agents and Chemotherapy, vol. 9, no. 3, pp. 406-413.
Huppert, M. ; Pappagianis, D. ; Sun, S. H. ; Gleason-Jordan, I. ; Collins, M. S. ; Vukovich, K. R. / Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo. In: Antimicrobial Agents and Chemotherapy. 1976 ; Vol. 9, No. 3. pp. 406-413.
@article{e0f8fe4027824f23b9a715fb012a48a5,
title = "Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo",
abstract = "Amphotericin B, the principal drug used for treating systemic mycoses possesses undesirable toxic properties. The ability of this antibiotic to potentiate antifungal activity of other compounds suggests that lower doses of amphotericin B could be used in combination with a second drug without loss of therapeutic efficacy. In vitro tests demonstrated that amphotericin B potentiated rifampin against the mycelial growth phase of Coccidioides immitis but not against the spherule endospore phase. Therapy for murine coccidioidomycosis with a combined amphotericin B rifampin regimen was not better than treatment with amphotericin B alone; in fact, combined drugs may have been even less effective. This would have clinical significance for therapy of concurrent infections.",
author = "M. Huppert and D. Pappagianis and Sun, {S. H.} and I. Gleason-Jordan and Collins, {M. S.} and Vukovich, {K. R.}",
year = "1976",
language = "English (US)",
volume = "9",
pages = "406--413",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo

AU - Huppert, M.

AU - Pappagianis, D.

AU - Sun, S. H.

AU - Gleason-Jordan, I.

AU - Collins, M. S.

AU - Vukovich, K. R.

PY - 1976

Y1 - 1976

N2 - Amphotericin B, the principal drug used for treating systemic mycoses possesses undesirable toxic properties. The ability of this antibiotic to potentiate antifungal activity of other compounds suggests that lower doses of amphotericin B could be used in combination with a second drug without loss of therapeutic efficacy. In vitro tests demonstrated that amphotericin B potentiated rifampin against the mycelial growth phase of Coccidioides immitis but not against the spherule endospore phase. Therapy for murine coccidioidomycosis with a combined amphotericin B rifampin regimen was not better than treatment with amphotericin B alone; in fact, combined drugs may have been even less effective. This would have clinical significance for therapy of concurrent infections.

AB - Amphotericin B, the principal drug used for treating systemic mycoses possesses undesirable toxic properties. The ability of this antibiotic to potentiate antifungal activity of other compounds suggests that lower doses of amphotericin B could be used in combination with a second drug without loss of therapeutic efficacy. In vitro tests demonstrated that amphotericin B potentiated rifampin against the mycelial growth phase of Coccidioides immitis but not against the spherule endospore phase. Therapy for murine coccidioidomycosis with a combined amphotericin B rifampin regimen was not better than treatment with amphotericin B alone; in fact, combined drugs may have been even less effective. This would have clinical significance for therapy of concurrent infections.

UR - http://www.scopus.com/inward/record.url?scp=0017187512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017187512&partnerID=8YFLogxK

M3 - Article

C2 - 1259400

AN - SCOPUS:0017187512

VL - 9

SP - 406

EP - 413

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -